2024
Our multidisciplinary team has identified a novel strategy for early diagnosis of Alzheimer’s disease (AD) based on molecules that bind selectively to soluble nonfibrillar aggregates of amyloid beta peptide that accumulate before plaque formation in the brain and cause neuronal cell death, leading to dementia. In animal models, our new tools detect amyloid beta aggregates prior to symptoms using positron emission tomography imaging. Research is now needed to validate specificity for imaging in a novel animal model and in human tissue samples. The proposed strategy is positioned to accelerate personalized care and improve quality of life for patients at risk for developing AD.
Sam Gandy, M.D., Ph.D.
Brigitte Guérin, Ph.D.
Shai Rahimipour, Ph.D.
William Lubell, Ph.D.
